✦ LIBER ✦

Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine

✍ Scribed by Tetsuya Hosaka; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Masahiro Kobayashi; Takashi Someya; Hitomi Sezaki; Norio Akuta; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada

Book ID: 106180129
Publisher: Springer Japan
Year: 2007
Tongue: English
Weight: 213 KB
Volume: 42
Category: Article
ISSN: 0944-1174
DOI: 10.1007/s00535-007-2008-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dynamics of lamivudine-resistant hepatit

Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy

✍ Samreen Ijaz; Catherine Arnold; Samir Dervisevic; Jana Mechurova; Nick Tatman; R 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

## Abstract Adefovir dipivoxil has been used alone or together with lamivudine to suppress lamivudine‐resistant hepatitis B virus (HBV). However, the dynamics of HBV populations under different selection pressures and their impact on treatment outcome are poorly understood. Pyrosequencing® was appl

Clinical course and predictive factors o

Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients

✍ Mashu Aizawa; Akihito Tsubota; Kiyotaka Fujise; Keiko Tatsuzawa; Midori Kono; Sa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract The aims of this study were to assess the long‐term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV‐DNA <2.6 log copies/ml at 12 months of

Early virological suppression is associa

Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B

✍ H. L.-Y. CHAN; V. W.-S. WONG; C.-H. TSE; A. M.-L. CHIM; H.-Y. CHAN; G. L.-H. WON 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB

Factors contributing to antiviral effect

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B

✍ Nao Kurashige; Naoki Hiramatsu; Kazuyoshi Ohkawa; Takayuki Yakushijin; Shinichi 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 321 KB

Mutations associated with the therapeuti

Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis

✍ Kazuyoshi Ohkawa; Tetsuo Takehara; Michio Kato; Aimi Kanada; Matsuo Deguchi; Mas 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract Factors influencing the therapeutic efficacy of adefovir dipivoxil added to continuing lamivudine have not been elucidated in lamivudine‐resistant patients with type B chronic hepatitis. The viral mutations influencing the efficacy of treatment with adefovir dipivoxil were investigated

Antiviral efficacy of combination therap

Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance

✍ Hyo-Joon Yang; Jeong-Hoon Lee; Yoon Jun Kim; Jung-Hwan Yoon; Hyo-Suk Lee 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract There is little clinical information on the management of hepatitis B virus (HBV) that is resistant to multiple drugs including entecavir (ETV). The present retrospective cohort study assessed the antiviral efficacy of ETV/adefovir dipivoxil (ADV) combination therapy for ETV‐resistant H